The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma
Ziccheddu B, Biancon G, De Philippis C, Bagnoli F, Maura F, Dugo M, Devecchi A, De Cecco L, Sensi M, Terragna C, Martello M, Bagratuni T, Kastritis E, Dimopoulos M, Cavo M, Carniti C, Montefusco V, Corradini P, Bolli N. The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma. Blood 2019, 134: 3056. DOI: 10.1182/blood-2019-122197.Peer-Reviewed Original ResearchMultiple myelomaSpeakers bureauProteasome inhibitorsTP53 mutationsAdvisory CommitteeHigh-dose melphalanMedian overall survivalHigh-risk featuresRefractory multiple myelomaTime of transplantHigh-risk lesionsLine of treatmentNext-generation sequencingBulk tumor populationWhole-exome sequencingInfluence of treatmentMCL1 upregulationOverall survivalRefractory casesComplete responseDisease courseMM patientsPrognostic valueImmunomodulatory agentsPathogenetic role